Table 3.
Absolute and relative inequalities in cancer incidence among men and women by district-level socioeconomic deprivation.
| Simple measures | Summary indices | |||||
|---|---|---|---|---|---|---|
| SRD (95% CI) | SRR (95% CI) | p-value | SII (95% CI) | RII (95% CI) | p-value | |
| ALL CANCERS (C00–C97)a | ||||||
| Men | 47.1 (29.7–64.6) | 1.07 (1.05–1.10) | <0.001 | 71.3 (47.8–94.9) | 1.11 (1.07–1.15) | <0.001 |
| Women | −4.5 (−18.3–9.4) | 0.99 (0.96–1.02) | 0.526 | −7.5 (−26.4–11.5) | 0.98 (0.95–1.02) | 0.440 |
| ORAL AND UPPER RESPIRATORY TRACT (C00–C06, C09–C14, C32) | ||||||
| Men | 6.6 (4.5–8.6) | 1.24 (1.16–1.33) | <0.001 | 9.8 (7.3–12.2) | 1.38 (1.28–1.50) | <0.001 |
| Women | 0.5 (−0.3–1.3) | 1.06 (0.96–1.17) | 0.246 | 0.4 (−0.5–1.3) | 1.05 (0.94–1.17) | 0.403 |
| ESOPHAGUS (C15) | ||||||
| Men | 2.3 (1.3–3.2) | 1.19 (1.11–1.28) | <0.001 | 2.5 (1.4–3.6) | 1.21 (1.11–1.31) | <0.001 |
| Women | −0.3 (−0.7–0.1) | 0.90 (0.79–1.02) | 0.106 | −0.3 (−0.8–0.1) | 0.89 (0.77–1.04) | 0.141 |
| STOMACH (C16) | ||||||
| Men | 5.2 (3.8–6.6) | 1.22 (1.16–1.29) | <0.001 | 6.7 (5.1–8.2) | 1.29 (1.22–1.37) | <0.001 |
| Women | 2.2 (1.3–3.0) | 1.17 (1.10–1.24) | <0.001 | 2.4 (1.5–3.3) | 1.19 (1.12–1.27) | <0.001 |
| COLORECTUM (C18–C20) | ||||||
| Men | 6.4 (2.8–10.1) | 1.07 (1.03–1.12) | 0.001 | 8.0 (3.6–12.4) | 1.09 (1.04–1.14) | <0.001 |
| Women | 1.7 (−0.9–4.3) | 1.03 (0.99–1.08) | 0.189 | 2.5 (−0.6–5.7) | 1.04 (0.99–1.10) | 0.115 |
| LIVER (C22) | ||||||
| Men | 0.3 (−1.2–1.7) | 1.02 (0.93–1.11) | 0.714 | 0.4 (−1.3–2.1) | 1.03 (0.92–1.14) | 0.632 |
| Women | 0.8 (0.3–1.3) | 1.16 (1.06–1.27) | 0.001 | 0.8 (0.3–1.4) | 1.17 (1.06–1.29) | 0.003 |
| PANCREAS (C25) | ||||||
| Men | 1.5 (0.3–2.7) | 1.07 (1.01–1.12) | 0.015 | 1.9 (0.6–3.3) | 1.09 (1.03–1.16) | 0.005 |
| Women | −0.3 (−1.1–0.5) | 0.98 (0.94–1.03) | 0.477 | −0.4 (−1.3–0.5) | 0.98 (0.93–1.03) | 0.379 |
| LUNG (C33–C34) | ||||||
| Men | 25.6 (20.5–30.7) | 1.33 (1.26–1.41) | <0.001 | 37.1 (30.5–43.7) | 1.50 (1.40–1.61) | <0.001 |
| Women | 2.2 (−1.0–5.5) | 1.06 (0.97–1.16) | 0.183 | 2.7 (−1.7–7.0) | 1.07 (0.96–1.21) | 0.232 |
| MALIGNANT MELANOMA OF SKIN (C43) | ||||||
| Men | −8.7 (−10.9–−6.5) | 0.72 (0.67–0.79) | <0.001 | −12.3 (−15.0–−9.5) | 0.64 (0.58–0.71) | <0.001 |
| Women | −5.8 (−8.1–−3.5) | 0.78 (0.71–0.86) | <0.001 | −8.3 (−11.3–−5.4) | 0.71 (0.63–0.80) | <0.001 |
| BREAST (C50) | ||||||
| Women | −7.4 (−13.4–−1.4) | 0.95 (0.92–0.99) | 0.016 | −12.0 (−19.6–−4.4) | 0.93 (0.88–0.97) | 0.002 |
| CERVIX UTERI (C53) | ||||||
| Women | 1.3 (0.4–2.2) | 1.12 (1.03–1.21) | 0.005 | 2.0 (1.0–3.0) | 1.19 (1.09–1.30) | <0.001 |
| OVARY (C56) | ||||||
| Women | −1.2 (−2.2–−0.2) | 0.93 (0.87–0.99) | 0.016 | −1.7 (−2.9–−0.6) | 0.90 (0.84–0.97) | 0.003 |
| PROSTATE (C61) | ||||||
| Men | 4.3 (−3.6–12.2) | 1.03 (0.98–1.07) | 0.286 | 2.6 (−7.7–12.9) | 1.02 (0.96–1.08) | 0.623 |
| KIDNEY (C64) | ||||||
| Men | 5.0 (3.3–6.6) | 1.21 (1.14–1.29) | <0.001 | 6.3 (4.3–8.3) | 1.28 (1.18–1.38) | <0.001 |
| Women | 3.2 (2.2–4.1) | 1.28 (1.19–1.38) | <0.001 | 4.1 (3.1–5.2) | 1.39 (1.28–1.51) | <0.001 |
| BLADDER (C67) | ||||||
| Men | 5.5 (3.3–7.7) | 1.20 (1.11–1.29) | <0.001 | 7.4 (4.7–10.0) | 1.27 (1.17–1.39) | <0.001 |
| Women | 1.4 (0.6–2.2) | 1.18 (1.08–1.29) | <0.001 | 1.6 (0.7–2.4) | 1.21 (1.09–1.34) | <0.001 |
| THYROID GLAND (C73) | ||||||
| Men | −2.2 (−2.8–−1.6) | 0.64 (0.57–0.72) | <0.001 | −2.8 (−3.4–−2.1) | 0.56 (0.49–0.64) | <0.001 |
| Women | −3.0 (−4.2–−1.7) | 0.76 (0.68–0.85) | <0.001 | −5.1 (−6.5–−3.6) | 0.62 (0.54–0.70) | <0.001 |
| LYMPHOID AND HEMATOPOIETIC NEOPLASMS (C81–C96) | ||||||
| Men | 5.0 (2.2–7.9) | 1.10 (1.04–1.16) | 0.001 | 5.5 (2.1–9.0) | 1.11 (1.04–1.18) | 0.002 |
| Women | 3.8 (2.0–5.7) | 1.11 (1.06–1.17) | <0.001 | 4.2 (2.0–6.5) | 1.12 (1.06–1.20) | <0.001 |
a
Without C44 and C77–C79; SRD, standardized rate difference (most vs. least deprived quintile); SRR, standardized rate ratio (most vs. least deprived quintile); SII, Slope index of inequality; RII, relative index of inequality; CI, confidence interval. All measures are age–standardized according to the 2013 European Standard Population.